AbbVie Inc

NYSE:ABBVUnited States

Today

Show headlines and story abstract

• DJ Correction to AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com, from 1 hour ago by Dow Jones

  1 hour ago by Dow Jones
  Companies Mentioned: LLY, RHHBY, DNLI, ABBV, VYGR
  By Bill Alpert Hopes are rising for better ways to deal with Alzheimer's disease. Late Monday, AbbVie announced an agreement to buy a firm that is testing a more effective way of battling the illness. AbbVie is spending $1.4 billion for Aliada, a start-up that is in Phase 1 testing of an antibody that can penetrate the blood-brain barrier better than approved Alzheimer's drugs like Eli Lilly's Kisunla or the Esai/ Biogen product Leqembi. That transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging antibodies. Chief among them is Roche Holding: Wednesday morning it will report interim Phase 2 results for its antibody trontinemab, which promises to be the best Alzheimer's treatment so far. The Lilly and Biogen antibodies were the first treatments shown to change the course of Alzheimer's, by getting the immune system to clear brain cells of the amyloid plaque that kills them. But because the brain's blood vessels present a barrier to large molecules such as antibodies, as little as 0.1% of plaque-targeting antibodies get to the brain. Both Roche and Aliada attach a protein to their antibodies that unlocks something called the transferrin receptor. That gets more of their treatment across the blood-brain barrier, so a lower dose could achieve higher efficacy with fewer side effects. In Madrid at 7:45 a.m. local time Wednesday, Roche is showing its latest data on trontinemab at a meeting called Clinical Trials on Alzheimer's Disease. In a preview at last month's shareholders' meeting, Roche said its antibody rapidly cleared amyloid plaque at relatively low doses, with few serious side effects. Roche is trademarking its blood-brain barrier-opening technology as "Brainshuttle." It expects the technique to also work in Parkinson's disease and other neurological afflictions. The final data from its Phase 2 Alzheimer's study will arrive in early 2025. If they look good, Roche hopes to move quickly into Phase three trials. AbbVie plunked down its $1.4 billion for Aliada without even having Phase 1 results in hand. If the results are good, AbbVie could be Roche's fast-follower across the blood-brain barrier. In research reports Tuesday, analysts pointed to other drug companies pursuing treatments that would penetrate the blood-brain barrier. Baird analyst Jack Allen noted that his Buy-rated Voyager Therapeutics has done animal research on such drugs. Denali Therapeutics has a number of neurology programs based on its Transport Vehicle technology, wrote B. Riley's Mayank Mamtani. It hopes to seek approval next year for a treatment of the rare disease known as Hunter Syndrome, but none of its Alzheimer's candidates are in clinical trials. Still, the analyst sees this week's AbbVie news as validation of his Buy rating on Denali stock. Write to Bill Alpert at william.alpert@barrons.com This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. Corrections & Amplifications Denali Therapeutics has a blood-brain barrier-crossing drug in late stage clinical trials, to treat the inherited disorder called Hunter Syndrome. An earlier version of this article incorrectly said Denali had no barrier-crossing neurological drug in trials. (END) Dow Jones Newswires October 31, 2024 17:25 ET (21:25 GMT)

• DJ AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com, from 1 hour ago by Dow Jones

  1 hour ago by Dow Jones
  Companies Mentioned: LLY, RHHBY, DNLI, ABBV, VYGR
  By Bill Alpert Hopes are rising for better ways to deal with Alzheimer's disease. Late Monday, AbbVie announced an agreement to buy a firm that is testing a more effective way of battling the illness. AbbVie is spending $1.4 billion for Aliada, a start-up that is in Phase 1 testing of an antibody that can penetrate the blood-brain barrier better than approved Alzheimer's drugs like Eli Lilly's Kisunla or the Esai/ Biogen product Leqembi. That transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging antibodies. Chief among them is Roche Holding: Wednesday morning it will report interim Phase 2 results for its antibody trontinemab, which promises to be the best Alzheimer's treatment so far. The Lilly and Biogen antibodies were the first treatments shown to change the course of Alzheimer's, by getting the immune system to clear brain cells of the amyloid plaque that kills them. But because the brain's blood vessels present a barrier to large molecules such as antibodies, as little as 0.1% of plaque-targeting antibodies get to the brain. Both Roche and Aliada attach a protein to their antibodies that unlocks something called the transferrin receptor. That gets more of their treatment across the blood-brain barrier, so a lower dose could achieve higher efficacy with fewer side effects. In Madrid at 7:45 a.m. local time Wednesday, Roche is showing its latest data on trontinemab at a meeting called Clinical Trials on Alzheimer's Disease. In a preview at last month's shareholders' meeting, Roche said its antibody rapidly cleared amyloid plaque at relatively low doses, with few serious side effects. Roche is trademarking its blood-brain barrier-opening technology as "Brainshuttle." It expects the technique to also work in Parkinson's disease and other neurological afflictions. The final data from its Phase 2 Alzheimer's study will arrive in early 2025. If they look good, Roche hopes to move quickly into Phase three trials. AbbVie plunked down its $1.4 billion for Aliada without even having Phase 1 results in hand. If the results are good, AbbVie could be Roche's fast-follower across the blood-brain barrier. In research reports Tuesday, analysts pointed to other drug companies pursuing treatments that would penetrate the blood-brain barrier. Baird analyst Jack Allen noted that his Buy-rated Voyager Therapeutics has done animal research on such drugs. Denali Therapeutics has a number of neurology programs based on its Transport Vehicle technology, wrote B. Riley's Mayank Mamtani. It hopes to seek approval next year for a treatment of the rare disease known as Hunter Syndrome, but none of its Alzheimer's candidates are in clinical trials. Still, the analyst sees this week's AbbVie news as validation of his Buy rating on Denali stock. Write to Bill Alpert at william.alpert@barrons.com This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. Corrections & Amplifications This article was corrected at 5:59 p.m. ET. Denali Therapeutics has a blood-brain barrier-crossing drug in late stage clinical trials, to treat the inherited disorder called Hunter Syndrome. The original version incorrectly said Denali had no barrier-crossing neurological drug in trials. (END) Dow Jones Newswires October 31, 2024 17:12 ET (21:12 GMT)

• DJ AbbVie Is Maintained at Buy by Citigroup, from 2 hours ago by Dow Jones

  2 hours ago by Dow Jones
  Companies Mentioned: ABBV
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ABBV/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 31, 2024 16:41 ET (20:41 GMT)
  

• DJ AbbVie Is Maintained at Neutral by UBS, from 3 hours ago by Dow Jones

  3 hours ago by Dow Jones
  Companies Mentioned: ABBV
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ABBV/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 31, 2024 15:45 ET (19:45 GMT)
  

• UBS Adjusts Price Target on AbbVie to $200 From $195, Maintains Neutral Rating, from 7 hours ago by MT Newswires

  7 hours ago by MT Newswires
  Companies Mentioned: ABBV
  11:14 AM EDT, 10/31/2024 (MT Newswires) -- AbbVie (ABBV) has an average outperform rating and price target range of $170 to $240, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major ban...